Search

Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most frequent causes of drug hypersensitivity reactions, affecting 1%-3% of general population; the prevalence of NSAID hypersensitivity is higher in patients with chronic rhinosinusitis, nasal polyposis, asthma, or chronic urticaria, affecting up to 30% of patients[1]. This is a prospective, real-life, observational study aimed to evaluate all direct and indirect health costs of patients that consulted in our outpatient clinic for suspected NSAID hypersensitivity reactions. One of the advantages of performing a study of NSAID hypersensitivity is de-labeling of purported NSAID hypersensitivity patients. [Extracted from the article]

Immediate and nonimmediate hypersensitivity reactions to iodinated contrast media (ICM) have been reported to occur in a frequency of about 0.5%‐3% of patients receiving nonionic ICM. The diagnosis and management of these patients vary among guidelines published by various national and international scientific societies, with recommendations ranging from avoidance or premedication to drug provocation test. This position paper aims to give recommendations for the management of patients with ICM hypersensitivity reactions and analyze controversies in this area. Skin tests are recommended as the initial step for diagnosing patients with immediate and nonimmediate hypersensitivity reactions; besides, they may also help guide on tolerability of alternatives. Re‐exposition or drug provocation test should only be done with skin test‐negative ICMs. The decision for performing either re‐exposition or drug provocation test needs to be taken based on a risk‐benefit analysis. The role of in vitro tests for diagnosis and pretreatment for preventing reactions remains controversial. [ABSTRACT FROM AUTHOR]

Drug hypersensitivity reactions (DHRs) are nowadays the third cause of allergy after rhinitis and asthma with a significant increase in prevalence in both adults and paediatric population with new drugs included as culprit. For this, DHRs represent not only a health problem but also a significant financial burden for affected individuals and health systems. Mislabelling DHRs is showing to be a relevant problem for both, false label of drug allergic and false label of nonallergic. All this reinforces the need to improve accurate diagnostic approaches that allow an appropriate management. Moreover, there is a need for training both, nonallergist stakeholders and patients to improve the reaction identification and therefore decrease the mislabelling. The use of allergy cards has shown to be relevant to avoid the induction of DHRs due to the prescription of wrong medication. Recent developments over the last 2 years and highlights about risk factors, diagnostic approaches, mechanisms involved as well as prevention actions, and management have been reviewed. In these papers, it has been outlined the need for correct diagnosis and de‐labelling of patients previously false‐reported as allergic, which will improve the management and treatment of patients with DHRs. [ABSTRACT FROM AUTHOR]